Benitec Biopharma Announces Positive Interim Clinical Results for BB-301 in OPMD

Article summary

Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301, showing robust and durable improvements in swallowing function for patients with Oculopharyngeal Muscular Dystrophy (OPMD).